

**RECEIVED**  
CENTRAL FAX CENTER

**APR 24 2006**

PTO/SB/82 (08-04)

Approved for use through 11/30/2005. OMB 0651-0036  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS</b>	Application Number	10/506,592
	Filing Date	September 3, 2004
	First Named Inventor	Andrew David Morely
	Art Unit	1625
	Examiner Name	Nolan, Jason Michael
	Attorney Docket Number	100659-1P US

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: **44992**

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with  
Customer Number:

**44992**

OR


<input type="checkbox"/> Firm or Individual Name	AstraZeneca Pharmaceuticals LP				
Address	Global Intellectual Property 35 Gatehouse Drive				
City	Waltham				
Country	USA	State	MA	Zip	02451
Telephone	(781) 839-4000			Fax	(781) 839-4121

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature			
Name	Tracey Bryant		
Date	13 JANUARY 2006.	Telephone	+44 (0) 1625 513228

NOTE: Signatures of all the inventors or its assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ \*Total of 1 forms are submitted.

**BEST AVAILABLE COPY**

PTO/SB/96 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Andrew David MorleyApplication No.: 10/506,592 Filed: September 3, 2004Entitled: INDOLE-AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN  
PHOSPHORAYLASE INHIBITORSAstraZeneca AB, a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %  
in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 016412, Frame 0080, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.  
(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

T. Bryant  
Signature13 JANUARY 2006  
DateTracey Bryant  
Printed or Typed Name

Telephone Number

Authorized Signer for Assignee  
Title: Patent Director, Oncology & Infection+44 (0) 1625 513228